Lineage Cell Therapeutics (LCTX) Other Non Operating Income (2016 - 2025)
Historic Other Non Operating Income for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Q3 2025 value amounting to $219000.0.
- Lineage Cell Therapeutics' Other Non Operating Income fell 5111.61% to $219000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year increase of 3223.14%. This contributed to the annual value of -$670000.0 for FY2024, which is 2316.18% down from last year.
- According to the latest figures from Q3 2025, Lineage Cell Therapeutics' Other Non Operating Income is $219000.0, which was down 5111.61% from $1.7 million recorded in Q2 2025.
- In the past 5 years, Lineage Cell Therapeutics' Other Non Operating Income ranged from a high of $1.7 million in Q2 2025 and a low of -$2.4 million during Q3 2021
- Its 5-year average for Other Non Operating Income is -$373210.5, with a median of -$386000.0 in 2024.
- In the last 5 years, Lineage Cell Therapeutics' Other Non Operating Income crashed by 29505.15% in 2022 and then skyrocketed by 54391.53% in 2025.
- Quarter analysis of 5 years shows Lineage Cell Therapeutics' Other Non Operating Income stood at -$1.7 million in 2021, then soared by 123.72% to $398000.0 in 2022, then soared by 214.57% to $1.3 million in 2023, then crashed by 130.83% to -$386000.0 in 2024, then skyrocketed by 156.74% to $219000.0 in 2025.
- Its Other Non Operating Income was $219000.0 in Q3 2025, compared to $1.7 million in Q2 2025 and -$231000.0 in Q1 2025.